| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699504 | Clinical Oncology | 2010 | 5 Pages |
Abstract
Patients with a prolonged TTF after first-line treatment are more likely to relapse with neck and axillary lymphadenopathy. The use of second-line chemotherapy, including rechallenge treatment, in this disease is a viable option for a selected group of MPM patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. Steer, G. Bough, A.R.A. Razak, G.J. Meachery, A. Hughes,